In a groundbreaking advancement in the treatment of metastatic urothelial cancer, a recent clinical trial has explored the synergistic potential of combining immune checkpoint inhibitors tremelimumab and durvalumab with the chemotherapeutic agent paclitaxel. This phase I/II ICRA trial, published in the prestigious Nature Communications, offers compelling evidence that dual immune modulation with or without chemotherapy may redefine therapeutic paradigms for this challenging malignancy. The innovative study meticulously investigates the safety profile, optimal dosing, and preliminary efficacy signals of these agents when administered simultaneously, charting a promising new course in oncologic therapeutics.

Urothelial carcinoma, predominantly affecting the bladder, represents a formidable oncological challenge due to its aggressive nature and propensity for metastasis upon progression. While immune checkpoint inhibitors have revolutionized cancer care by unleashing the host’s immune system against tumor cells, their efficacy as monotherapy in advanced urothelial cancer remains variable. Tremelimumab, a monoclonal antibody targeting CTLA-4, and durvalumab, an anti-PD-L1 antibody, function by disrupting distinct immunosuppressive pathways that tumors exploit to evade immune detection. The rationale behind combining these agents with paclitaxel—a cytotoxic drug known for interfering with microtubule dynamics—lies in the complementary mechanisms that might potentiate antitumor responses.

The trial enrolled patients with histologically confirmed metastatic urothelial cancer who had exhausted or were ineligible for standard therapeutic options. Participants received varying regimens comprising tremelimumab alone, tremelimumab plus durvalumab, and either combination with paclitaxel. This design sought to delineate the safety thresholds and dose-limiting toxicities while enabling exploratory analyses of clinical outcomes such as progression-free survival and objective response rates. Detailed immune profiling and biomarker assessments accompanied the clinical evaluations to decipher correlates of response and resistance.

Initial data reveal that the combination treatments are generally well tolerated, with adverse events consistent with known profiles of checkpoint inhibitors and chemotherapy. Immune-related adverse events—such as dermatitis, colitis, and endocrinopathies—were manageable within established guidelines, emphasizing the importance of vigilant monitoring and timely intervention. Importantly, no unexpected synergistic toxicities emerged, suggesting that these agents can be safely coadministered without exacerbating systemic toxicity.

From an efficacy standpoint, tremelimumab combined with durvalumab and paclitaxel demonstrated encouraging antitumor activity, surpassing response rates historically observed with any single agent in this patient cohort. Objective responses included significant tumor burden reductions, with some patients experiencing durable disease stabilization or partial remission. Notably, the addition of paclitaxel appeared to enhance immunogenic cell death, potentially promoting antigen presentation and T-cell activation, thus amplifying the therapeutic window of the checkpoint blockade.

Correlative translational studies provided insights into the immunological milieu shaping treatment responses. Tumor biopsies and peripheral blood analyses highlighted increased infiltration of CD8+ cytotoxic T lymphocytes and a concomitant decrease in immunosuppressive regulatory T cells in responders. Furthermore, upregulation of interferon-gamma signaling pathways and enhanced expression of antigen processing machinery were observed, aligning with the hypothesis that chemotherapy-induced immunogenicity synergizes with checkpoint inhibition to invigorate antitumor immunity.

Another pivotal observation was the heterogeneity in patient outcomes, underscoring the necessity for biomarker-driven patient stratification. Molecular profiling identified tumor mutational burden and PD-L1 expression levels as potential predictive biomarkers, although their roles require further validation. Intriguingly, emerging evidence suggests that tumor microenvironment features—such as cytokine profiles and myeloid cell populations—may also influence responsiveness, opening new avenues for personalized immunotherapy approaches.

The trial’s phased escalation design allowed for adaptive modifications based on interim results, optimizing dosing regimens to balance efficacy and safety. These methodological strengths enhance the reliability of conclusions drawn and set a precedent for future combination trials in urothelial carcinoma and beyond. Additionally, pharmacokinetic analyses confirmed that neither agent significantly altered the metabolism of the others, supporting their compatibility in combination therapies.

This landmark investigation contributes critical knowledge to the evolving landscape of bladder cancer treatment by demonstrating how rationally designed combinations of immune checkpoint inhibitors and chemotherapies can elicit potent antitumor effects in metastatic disease. Given the historically poor prognosis for advanced urothelial cancer, these findings herald a new era where multi-agent immunomodulation may offer renewed hope for patients. However, broader phase III studies will be essential to confirm survival benefits and thoroughly characterize long-term safety.

Moreover, the translational components embedded within this study exemplify the growing trend towards integrating laboratory science with clinical oncology. Such integrative approaches are crucial for unraveling the complex interplay between tumor biology and therapeutic interventions, ultimately facilitating the development of more effective, tailored treatments. The ICRA trial represents an exemplar of precision medicine in action, advancing beyond one-size-fits-all approaches towards nuanced, biomarker-informed strategies.

While the current research focuses on metastatic urothelial carcinoma, the implications extend to other malignancies where immune evasion is a critical obstacle. The dual blockade of CTLA-4 and PD-L1 pathways in concert with chemotherapeutic agents may prove universally applicable, prompting parallel investigations across diverse cancer types. Furthermore, understanding the mechanisms that underlie response and resistance could inform the design of next-generation immunotherapies, including combination regimens incorporating novel agents such as oncolytic viruses, vaccines, or cell-based therapies.

In the broader context of cancer immunotherapy, the trial reinforces the concept that combining immune checkpoint inhibitors with traditional cytotoxic chemotherapy can create a more hostile environment for cancer cells while simultaneously activating immune effector functions. This synergistic interaction leverages the strengths of both modalities: chemotherapy disrupts tumor cell replication and induces immunogenic cell death, while checkpoint inhibitors relieve inhibitory signals that dampen T-cell activity. Together, they orchestrate a multifaceted assault on cancer.

The success of this approach depends heavily on careful patient selection, vigilant management of immune-related adverse events, and comprehensive biomarker development. As immune therapies increasingly become standard in oncology, multidisciplinary collaborations between clinicians, immunologists, and computational biologists will be vital to fully harness their potential. The ICRA trial epitomizes such collaborative effort, merging clinical expertise with cutting-edge immunological research.

In summary, the phase I/II ICRA trial investigating tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer delineates a compelling therapeutic strategy blending checkpoint blockade and chemotherapy. It underscores important principles regarding safety, efficacy, and mechanistic synergy while illuminating paths for future exploration. As the oncology community eagerly awaits results from larger confirmatory studies, this trial stands as a milestone in the continuous quest to improve outcomes for patients facing this formidable disease.

---

Subject of Research: Combination immunotherapy with tremelimumab and durvalumab alongside paclitaxel chemotherapy in metastatic urothelial cancer.

Article Title: Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.

Article References: Einerhand, S.M.H., Ali, H., Wong, S.Q. et al. Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74570-3

Image Credits: AI Generated

Laminin subunit beta 3 (LAMB3) has emerged as a critical player in the molecular landscape of cancer, yet its precise role in gastric cancer (GC) progression has remained elusive until now. A groundbreaking study published in the British Journal of Cancer unravels the intricate mechanisms by which LAMB3 exacerbates malignancy in GC, shedding light on a novel molecular axis that could revolutionize therapeutic approaches. This research uncovers how LAMB3 orchestrates the sustained activation of the PI3K-Akt pathway—one of the most prominent signaling routes involved in tumor growth and survival—through targeted degradation of PHLPP2 mRNA mediated by the RNA-binding protein SAMD4A.

Gastric cancer continues to rank among the leading causes of cancer mortality worldwide, with its complex molecular underpinnings posing a significant challenge to effective treatment. Despite advances in understanding various oncogenic drivers, the involvement of extracellular matrix components like LAMB3 has been underappreciated. Laminins, as glycoproteins critical for basement membrane structure and signaling, influence cell adhesion, migration, and differentiation. The aberrant overexpression of LAMB3 in various cancers hinted at its potential role in tumor aggressiveness, yet the mechanistic details remained uncharted until the present study’s in-depth molecular analyses.

The authors employed a comprehensive experimental framework combining transcriptomic analysis, RNA immunoprecipitation, and functional assays in gastric cancer cell lines and murine xenograft models. They demonstrated that LAMB3 upregulation correlates with increased GC cell proliferation, invasion, and metastatic potential. More strikingly, LAMB3 was found to exert these oncogenic effects by destabilizing PHLPP2 mRNA, a known tumor suppressor that negatively regulates the PI3K-Akt signaling axis. This discovery positions LAMB3 as a pivotal regulator of intracellular signaling networks that propel oncogenesis.

At the heart of this regulatory pathway lies SAMD4A, an RNA-binding protein previously unlinked to gastric cancer pathophysiology. The study reveals that LAMB3 enhances the interaction between SAMD4A and PHLPP2 mRNA, promoting its degradation through post-transcriptional mechanisms. This SAMD4A-mediated mRNA decay leads to a marked reduction in PHLPP2 protein levels, unleashing hyperactivation of the PI3K-Akt pathway. Such persistent signaling drives uncontrolled cellular proliferation and survival, hallmark features of aggressive cancer phenotypes.

Mechanistically, the suppression of PHLPP2 removes a vital check on Akt phosphorylation, facilitating an unchecked flow of pro-survival signals inside the cancer cells. The PI3K-Akt pathway modulates diverse cellular functions, including metabolism, apoptosis resistance, and cell cycle progression. By unraveling this axis, the study prominently positions LAMB3—and its downstream effectors—as promising biomarkers and therapeutic targets in GC, where tailored interventions are urgently needed.

Notably, the research team extended their findings to patient-derived GC tissues, confirming that elevated LAMB3 expression significantly correlates with poor prognosis and advanced disease stages. The clinical relevance strengthens the translational potential of targeting the LAMB3-SAMD4A-PHLPP2 axis, suggesting that disrupting this molecular cascade might curtail tumor progression and improve patient outcomes.

Beyond the intrinsic mechanistic insights, the study raises intriguing possibilities for drug development. Small molecules or RNA-based therapeutics that inhibit LAMB3 expression or interfere with SAMD4A’s binding to PHLPP2 mRNA could restore tumor suppressor function and dampen aberrant signaling. Given the centrality of PI3K-Akt in many cancers, such interventions might have broad applicability beyond just gastric malignancies, positioning this discovery at the forefront of precision oncology.

Moreover, the findings provoke a reevaluation of how extracellular matrix components, traditionally viewed as structural elements, actively participate in intracellular oncogenic signaling. The delineation of LAMB3’s role in manipulating RNA stability via SAMD4A opens a relatively unexplored frontier in cancer biology: the crosstalk between the extracellular milieu and post-transcriptional gene regulation. This interplay hints at a complex regulatory network that underpins cancer cells’ adaptability and survival in hostile microenvironments.

The study also highlights the importance of integrating multi-omics data to dissect the sophisticated molecular interactions governing cancer progression. Through the use of advanced RNA immunoprecipitation and sequencing techniques, the researchers mapped the dynamic interactions between RNA-binding proteins and specific mRNA targets, elucidating a critical post-transcriptional regulatory node controlled by LAMB3. Such approaches exemplify the power of cutting-edge molecular biology tools in unveiling hidden layers of cancer biology.

Future research is poised to explore whether similar mechanisms operate in other epithelial cancers where LAMB3 is dysregulated. Comparative analyses across tumor types could validate the universality of this pathway, potentially expanding the clinical impact of these findings. Furthermore, understanding how LAMB3 expression itself is regulated, including potential epigenetic and transcriptional modulators, could unveil additional therapeutic leverage points.

Identifying effective inhibitors of the LAMB3-SAMD4A interaction stands as an exciting therapeutic frontier. While challenging, the small interface between RNA-binding proteins and target mRNAs offers a unique opportunity to develop molecules with high specificity and minimal off-target effects. Collaboration between molecular biologists, chemists, and clinical researchers will be critical to translate these molecular insights into viable therapies.

In summary, this landmark study elucidates a novel molecular mechanism whereby LAMB3 promotes gastric cancer progression through the SAMD4A-mediated degradation of PHLPP2 mRNA, sustaining PI3K-Akt signaling. By connecting extracellular matrix components to post-transcriptional gene regulation and oncogenic signaling, it not only advances fundamental understanding of gastric cancer biology but also charts a promising path toward innovative treatment strategies. As gastric cancer continues to exact a heavy toll worldwide, such pioneering research offers new hope for improved diagnosis, prognosis, and therapeutic intervention.

The implications of this discovery extend beyond the realm of gastric cancer, potentially influencing broader fields of oncology and RNA biology. As the scientific community delves deeper into the non-canonical functions of extracellular proteins and RNA-binding factors, the intricate tapestry of cancer’s molecular underpinnings becomes progressively clearer. The LAMB3-SAMD4A-PHLPP2 axis may well become a focal point in the ongoing quest to outmaneuver cancer at its molecular roots.

With continued investment in translational research and clinical trials inspired by these findings, the next decade could herald significant breakthroughs in managing gastric cancer and related malignancies. This study stands as a testament to the power of multidisciplinary approaches in tackling one of humanity’s most formidable health challenges, combining molecular precision with clinical urgency to pave the way toward a future where gastric cancer progression can be effectively stalled or reversed.

---

Subject of Research: Molecular mechanisms driving gastric cancer malignancy involving LAMB3-mediated regulation of mRNA stability and signaling pathways.

Article Title: LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation.

Article References:
Guo, J., Cai, F., Zhang, M. et al. LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03496-w

Image Credits: AI Generated

DOI: 2026-06-17

Most of us have used the sniff test to decide whether a slightly expired bottle of milk or a week-old box of takeout is still good to eat. But while the human nose can be quite astute, it doesn't always catch everything. Each year, millions of people in the U.S. are sickened by food-borne pathogens that thrive in undercooked or spoiled food.

The preliminary U.S.-Iran deal temporarily waives restrictions that have limited the country’s oil sales and how much money it has been able to make from those exports.

© Atta Kenare/Agence France-Presse — Getty Images

Tokenmaxxing was the hottest trend in Silicon Valley earlier this year, with CEOs encouraging employees to push AI usage as far as it would go. Then the bill came due. Uber reportedly blew through its annual AI budget in a few months, some companies cut Claude licenses for parts of their org, and Meta killed its internal leaderboard.  This tension between […]

In a landmark achievement for cardiovascular care, one hundred hospitals across the United States have been awarded the prestigious American College of Cardiology (ACC) HeartCARE Center designation. This recognition represents the pinnacle of commitment to delivering superior, patient-centered cardiovascular treatment. Introduced in 2018, the HeartCARE Center designation is the ACC’s most esteemed accolade for hospitals and health systems, acknowledging institutions that exhibit sustained clinical excellence through comprehensive accreditation, rigorous performance monitoring via data analytics, and ongoing quality improvement processes.

This milestone reflects the ACC’s unwavering dedication to advancing the standards by which cardiovascular services are delivered nationwide. The hospitals recognized demonstrate adherence to evidence-based clinical protocols, participation in continuous quality enhancement initiatives, and the achievement of measurable patient outcomes that transcend regional disparities. Steven B. Deitelzweig, MD, MMM, FACC, chair of the ACC Accreditation Oversight Committee, emphasized the significance of this accomplishment, highlighting that these institutions collectively enhance cardiovascular care quality, ensuring access for patients wherever they reside.

The HeartCARE Center designation is conferred upon organizations that meet stringent criteria encompassing participation in a minimum of two ACC Accreditation Services programs and engagement with National Cardiovascular Data Registry (NCDR) registries. These registries serve as pivotal platforms for tracking and benchmarking clinical outcomes, enabling hospitals to pinpoint and bridge gaps in guideline-based care implementation. Furthermore, targeted quality improvement campaigns such as the Patient Navigator Program: Focus MI support institutions in closing those gaps through structured, scientifically grounded interventions.

Beyond accreditation and registry participation, the HeartCARE Center program integrates robust continuous performance measurement mechanisms. This integration fosters a culture of accountability and data-driven decision-making within hospitals, enabling them to consistently execute guideline-directed care pathways. The approach is designed not only to improve clinical outcomes for cardiovascular patients but also to enhance process efficiency and interprofessional collaboration across care teams, thereby standardizing high-quality care delivery throughout participating institutions.

As an integral component of the ACC’s broader Quality Improvement for Institutions initiative, the HeartCARE Center designation symbolizes organizational leadership in sustainable quality improvement. These hospitals exemplify best practices in process optimization, specialty-specific accreditation, clinical staff development, and active engagement with their surrounding communities. Collectively, these elements work synergistically to establish a new benchmark for coordinated, patient-centered cardiovascular care, expanding patient access to state-of-the-art heart health interventions locally.

By earning the HeartCARE Center designation, hospitals demonstrate not just isolated achievements but a persistent commitment to maintaining and advancing quality care across the entire spectrum of cardiovascular medicine. Dr. Deitelzweig noted that the rigorous standards required for designation translate into tangible benefits for patients, including improved survival rates, reduced complication incidences, and broader availability of the latest evidence-supported therapies. This systematic elevation of care quality promises to transform cardiovascular outcomes on a national scale.

The ACC’s strategic emphasis on integrating data from accreditation services and NCDR registries enables participating institutions to continuously refine clinical protocols in response to emerging evidence and outcome trends. This data-centric framework underpins the excellence recognized by the HeartCARE Center program, equipping hospitals with actionable insights for enhancing care pathways, reducing practice variability, and advancing the science of cardiovascular treatment delivery.

Technological advancements and sophisticated analytics play central roles in this process improvement paradigm. The ability to harness large-scale clinical data sets from the NCDR registries facilitates risk-adjusted benchmarking, enabling institutions to evaluate performance relative to national standards. This capability supports precision targeting of quality improvement efforts—ensuring resources are effectively allocated to areas with the greatest potential to impact patient care outcomes.

Community outreach and patient engagement initiatives are further hallmarks of HeartCARE Centers. These institutions not only excel internally but also proactively extend their knowledge and services beyond hospital walls. By fostering partnerships with local health organizations and enhancing public health education, HeartCARE Centers contribute to the prevention and early detection of cardiovascular disease, thereby addressing systemic health disparities and promoting holistic cardiovascular wellness.

Moreover, the multidisciplinary nature of cardiovascular care teams within HeartCARE Centers underscores the program’s emphasis on comprehensive treatment. Cardiologists, cardiac surgeons, nurses, rehabilitation specialists, and other healthcare professionals collaborate seamlessly to deliver continuity of care that is responsive to individual patient needs. This integrated care model has been shown to enhance adherence to treatment plans, improve functional recovery, and reduce hospital readmission rates.

Sustained professional education and credentialing efforts complement these clinical advancements, ensuring that healthcare providers within HeartCARE Centers remain at the forefront of cardiovascular medicine. The ACC’s broader infrastructure supports these goals through its renowned JACC journals, certification programs, and educational symposia, cultivating a workforce primed to apply innovative therapies grounded in rigorous scientific evidence.

Collectively, the achievement of 100 HeartCARE Center designations signals a transformative moment for cardiovascular care delivery in the United States. The program’s emphasis on data-driven quality improvement, comprehensive accreditation, and community-centered care sets a new standard that other healthcare disciplines may emulate. As more hospitals join the ranks of HeartCARE Centers, patients nationwide stand to benefit from enhanced outcomes, greater consistency in treatment, and access to cutting-edge, guideline-based cardiovascular therapies.

For those interested in reviewing the complete listing of hospitals designated as ACC HeartCARE Centers, further information is accessible through the ACC’s official platform. This transparency aids healthcare leaders, clinicians, and patients alike in identifying centers that exemplify clinical excellence and serves to incentivize continued quality advancements in cardiovascular medicine.

The American College of Cardiology remains steadfast in its mission to transform cardiovascular care globally. With a community exceeding 60,000 cardiovascular professionals across more than 140 countries, the ACC drives innovation, education, and advocacy, dedicated to optimizing heart health outcomes through scientific rigor and clinical leadership. The HeartCARE Center designation exemplifies this mission, heralding a future in which standardized, high-quality cardiovascular care is universally accessible.

---

News Publication Date: Not specified in the source content.

Web References: https://cvquality.acc.org/accreditation/heartcare-center-recognition-program/participating-facilities

Keywords: Cardiovascular care, HeartCARE Center designation, American College of Cardiology, ACC Accreditation, Quality Improvement, NCDR registries, Patient-centered care, Evidence-based treatment, Cardiovascular outcomes, Clinical excellence, Data-driven healthcare, Cardiology hospitals

In a groundbreaking advancement for artificial intelligence in healthcare, researchers at Mass General Brigham have unveiled BRIDGE, a comprehensive multilingual benchmark designed to critically assess how effectively large language models (LLMs) comprehend and interpret clinical patient-care text. Unlike existing AI evaluation metrics that rely primarily on structured and standardized medical exam questions, BRIDGE is engineered to engage with the multifaceted and complex language found in real-world clinical communications, including electronic health records (EHRs), case reports, and patient-doctor consultations, across nine different languages. This innovation represents a transformative step toward making AI tools more reliable and contextually aware in actual healthcare settings.

The existing paradigm in medical AI evaluation has predominantly centered on licensing exam questions composed in a controlled, formalized medical lexicon. These assessments, while rigorous, often fall short of reflecting the nuanced, variable, and sometimes ambiguous language used in actual clinical environments. The BRIDGE benchmark circumvents this limitation by employing authentic clinical texts, which capture the complexities and heterogeneity inherent to patient care dialogues, medical documentation, and clinical decision-making processes. This shift brings essential granularity and relevance to model performance metrics, providing clinicians and developers with more actionable insights.

The creators of BRIDGE demonstrated the stark contrast in performance between conventional exam-based evaluations and real-world clinical comprehension. For instance, the highest-performing LLM evaluated scored impressively on standard medical exams, achieving up to 92%. However, when subjected to BRIDGE’s rigorous clinical text test, the same model’s proficiency plummeted to only 44.8%. This significant disparity exposes considerable gaps in the AI’s ability to grasp the subtle clinical context, implicit meanings, and domain-specific language patterns prevalent in healthcare communications.

To validate the robustness and breadth of BRIDGE, the research team conducted a systematic performance evaluation of 95 distinct LLMs sourced from 59 different clinical AI initiatives. These models were subjected to a comprehensive battery of real-world clinical tasks encompassing the entire patient care continuum, ranging across 14 medical specialties. The tasks included patient triage, extraction of critical information from records, diagnostic reasoning, prognostic forecasting, and administrative functions such as billing code assignment. This extensive benchmarking provides a panoramic view of LLM capabilities and limitations in diverse clinical scenarios.

One of the more innovative features of BRIDGE is its public and continuously updated leaderboard hosted on the Hugging Face platform. This dynamic leaderboard catalogs the performance metrics of over 100 LLMs, enabling stakeholders including clinicians, health administrators, and AI developers to track comparative model efficacy in near real-time. The leaderboard thus fosters transparency and spurs iterative improvements by highlighting strengths and vulnerabilities within specific clinical tasks or language domains.

Another salient discovery made possible by BRIDGE is the identification of variability in AI performance across different medical specialties. Given that the benchmark corpus includes nine languages, the tool also illuminates disparities in model effectiveness when dealing with non-English clinical texts. This multilingual adaptability is particularly crucial as healthcare becomes more globally interconnected, underscoring the urgent need to develop culturally and linguistically sensitive AI applications that avoid exacerbating health inequities.

The scientific rigor of BRIDGE is underscored by its deep collaboration among experts spanning pharmacoepidemiology, pharmacoeconomics, clinical medicine, and computational modeling. The team includes senior authors such as Jie Yang, PhD, and Joshua Lin, MD, along with co-first authors Jiageng Wu and Bowen Gu, whose collective expertise was critical in ensuring the benchmark’s relevance and accuracy. Such interdisciplinary engagement is vital for bridging the gap between AI innovation and clinical applicability.

BRIDGE’s architecture and methodology leverage advanced computational simulation and modeling techniques, facilitating nuanced task designs that mimic real clinical workflows. This approach allows the benchmark to capture the dynamic and context-rich nature of clinical text interactions, incorporating elements like colloquial doctor-patient exchanges, complex diagnostic narratives, and procedural documentation. Consequently, BRIDGE functions as a high-fidelity proxy for real healthcare communication scenarios, offering a much-needed calibration tool for medical LLMs.

Funding generously provided by the Patient-Centered Outcomes Research Institute, the National Institutes of Health, and institutional scholarships reflects the strategic priority placed on refining AI’s role in healthcare delivery. Moreover, the rigorous conflict of interest disclosures and adherence to institutional compliance underscore the study’s commitment to transparency and ethical research standards. These factors enhance the credibility of BRIDGE as a benchmark tool destined to influence clinical AI development profoundly.

Importantly, BRIDGE is more than a passive evaluation tool—it is a catalyst for elevated AI design tailored to the clinical domain. By exposing the blind spots and differential performance across specialties and languages, it empowers AI developers to iterate more purposefully, embedding clinical nuance and real-world complexity into model training. This iterative feedback loop has the potential to accelerate the maturation of AI models from theoretical capabilities to practical clinical decision-support systems.

The release of BRIDGE is poised to address one of the persistent challenges in clinical AI—trust. Reliable understanding of patient-care language is paramount to fostering clinician confidence in AI-assisted diagnoses, prognoses, and patient management recommendations. The benchmark’s capacity to expose and rectify shortcomings before clinical deployment mitigates risks of errors caused by misinterpretation of nuanced clinical text, thereby safeguarding patient safety and improving care outcomes.

In closing, BRIDGE exemplifies a paradigm shift that acknowledges the inherent complexities of clinical language and seeks to elevate the fidelity of AI’s interpretative functions accordingly. As healthcare continues its digital transformation, integrating intelligent systems into everyday practice demands benchmarks as sophisticated and reflective as the environments they serve. BRIDGE sets a new gold standard in this endeavor, bridging the divide between cutting-edge AI performance and meaningful clinical utility.

Subject of Research: People

Article Title: BRIDGE: benchmarking large language models for understanding real-world clinical practice texts

News Publication Date: 17-Jun-2026

Web References:

• Mass General Brigham
• Nature Biomedical Engineering Article
• BRIDGE Medical Leaderboard

References: Wu, J. et al. “BRIDGE: Benchmarking Large Language Models for Understanding Real-world Clinical Practice Text” Nature Biomedical Engineering DOI: 10.1038/s41551-026-01719-2

Keywords: Artificial intelligence, machine learning, clinical medicine, large language models, electronic health records, multilingual AI, clinical text comprehension, medical AI benchmarking, healthcare AI, patient care AI

A groundbreaking hospital-based study conducted in India sheds new light on the complex and often controversial relationship between lifestyle factors and prostate cancer risk. Published in the April 28, 2026 issue of Oncoscience, this investigation provides intriguing evidence that certain modifiable habits, specifically coffee and meat consumption, may significantly reduce the likelihood of developing prostate cancer among men. This revelation emerges despite prostate cancer being the world’s second most prevalent malignancy in men and a critical contributor to cancer-related mortality.

The research was spearheaded by Maya Kulshekar and Anuradha B. Patil at the Department of Biochemistry, Jawaharlal Nehru Medical College, part of the KLE Academy of Higher Education and Research in Karnataka, India. Their work comes at a crucial moment when the incidence of prostate cancer in India is poised to rise markedly, underscoring the urgent need to identify interventions grounded in modifiable risk behaviors.

In this rigorously designed study, 72 men with histopathologically confirmed prostate cancer were compared to 132 control individuals diagnosed with benign prostatic hyperplasia (BPH). The investigators carefully examined a suite of lifestyle factors—ranging from tobacco use and alcohol consumption to dietary patterns including tea, coffee, and meat intake, as well as occupational exposure linked to farming. Thorough multivariate logistic regression analyses allowed the team to adjust for confounding variables, thereby refining the associations between these factors and prostate cancer risk.

The findings revealed a striking inverse association between coffee consumption and prostate cancer risk, translating to an approximate 65% reduction in odds after adjustment for potential confounders. Meat consumption similarly demonstrated a protective effect, associated with a roughly 48% decreased risk. These results challenge some conventional nutritional beliefs and highlight the nuanced role diet may play in modulating prostate oncogenesis.

Contrastingly, the study found no statistically significant correlation between alcohol consumption, tobacco chewing, smoking, tea intake, or farming-related occupational exposure and prostate cancer once confounding factors were accounted for. Initial univariate analyses suggested elevated risk linked to smoking and tobacco chewing; however, these associations dissipated under multivariable scrutiny, suggesting the potential influence of other interacting factors.

The biochemical mechanisms underpinning these associations were thoughtfully explored by the authors. Coffee is a complex beverage rich in bioactive compounds including caffeine, cafestol, kahweol, and a spectrum of antioxidant polyphenols. These molecules have been extensively studied for their anti-inflammatory and antioxidant properties, implicating them in pathways that may suppress malignant transformation or tumor progression. Their capacity to modulate cellular stress responses, DNA repair, and immune regulation positions coffee as a potent functional food in cancer prevention paradigms.

Similarly, meat contains constituents such as trans-vaccenic acid, an unsaturated fatty acid that has been observed in some experimental models to influence immune responses and cellular signaling pathways relevant to oncogenesis. Notwithstanding, the study authors caution that the protective role of meat is complicated by the heterogeneity inherent in types of meat, cooking methods, and quantity consumed—parameters that were not stratified in this investigation. The metabolic and molecular consequences of processed versus unprocessed meats or the generation of carcinogenic compounds during certain cooking processes remain pivotal confounders warranting further rigorous examination.

This research importantly acknowledges the broader scientific context where prior epidemiological studies have reported inconsistent and at times contradictory findings regarding coffee, meat, tobacco, tea, and alcohol in relation to prostate cancer risk. This inconsistency may stem from differences in study design, dietary assessment methods, population genetics, and environmental factors across cohorts. The current study’s contribution lies in focusing on an Indian population, thereby addressing a geographic and ethnic gap in the literature.

The methodological design, while robust, is not without limitations. The single-center hospital-based sample, and relatively modest cohort size, may affect the generalizability of the findings. Additionally, potential recall bias in self-reported lifestyle habits and the absence of quantitative dietary intake measures restrict the granularity of exposure assessment. The authors advocate for larger, multicenter, and longitudinal studies with comprehensive dietary and lifestyle quantification to validate and expand upon these preliminary observations.

This investigation marks an important step toward understanding how modifiable lifestyle factors could temper the risk of prostate cancer. By highlighting coffee and meat intake as potentially protective, the study invites a reevaluation of dietary guidelines and preventive oncology strategies within the Indian context and beyond. The mechanistic insights further fuel the search for bioactive compounds that could be leveraged in therapeutic or nutraceutical formulations.

Ultimately, these findings reinforce the imperative for personalized medicine approaches that integrate lifestyle, genetic, and environmental data to optimize cancer prevention and management. They also echo broader calls within the oncological community to pursue open-access, multidisciplinary research that bridges molecular science with public health imperatives.

While the findings demand cautious interpretation, they open an exciting avenue for leveraging everyday dietary choices as part of a comprehensive prostate cancer risk reduction strategy. As prostate cancer incidence is projected to escalate, especially in rapidly modernizing societies, these insights provide a timely beacon for clinicians, researchers, and policy makers alike.

The study’s implications extend beyond prostate cancer, emphasizing a holistic perspective on how complex interplays of diet, lifestyle, and biological mechanisms coalesce to impact carcinogenesis. It epitomizes the potential for traditional epidemiological research, augmented by advanced statistical modeling, to generate actionable knowledge that may ultimately improve patient outcomes on a population scale.

Researchers and clinicians interested in this expanding field are encouraged to follow ongoing and future work from this team and related cohorts worldwide, as the quest to decipher modifiable risk factors of prostate cancer continues to gain precision and impact.

---

Subject of Research: People
Article Title: Modifiable risk factors of prostate cancer: Insights from a hospital-based study
News Publication Date: 28-Apr-2026
Web References: https://doi.org/10.18632/oncoscience.657
Image Credits: Copyright © 2026 Kulshekar et al. Creative Commons Attribution License (CC BY 4.0)
Keywords: modifiable risk factors, prostate cancer, awareness, India, molecular mechanism

Physical therapy for stroke survivors has long relied on the physical presence and hands-on expertise of therapists walking alongside their patients. Now, a remarkable technological leap is reshaping this dynamic. Researchers at Northwestern University in collaboration with Shirley Ryan AbilityLab have unveiled a revolutionary rehabilitation system that forges a direct, real-time link between therapists and patients via robotic exoskeletons. This novel system, known as Therapist-Exoskeleton-Patient Interaction (TEPI), ushers in a new era of highly adaptive, personalized post-stroke gait therapy.

At the heart of TEPI lies a pair of lower-limb exoskeletons worn by the therapist and the stroke survivor, virtually coupled at the hips and knees through a sophisticated control interface. The virtual connection mimics the behavior of springs and shock absorbers, dynamically transmitting forces and movements between the two exoskeletons. This bidirectional, compliant coupling enables therapists to intuitively influence patient gait patterns in real time, offering a level of interaction that is vastly more nuanced than conventional robotic or manual therapies.

Traditional stroke rehabilitation often involves therapists physically assisting patients through limited aspects of movement, constrained by human strength and availability. In contrast, TEPI leverages robotics to augment the therapist’s capacity, delivering whole-body gait training that adjusts fluidly to the patient’s evolving performance. The hands-on adaptability of therapists is thus preserved but enhanced with robotic precision and scalability, facilitating more comprehensive, sustained walking practice without requiring multiple caregivers.

The core engineering breakthrough enabling TEPI is a control framework that models the mechanical interaction between therapist and patient exoskeletons as a coupled spring-damper system. This design imparts compliance and responsiveness, harmonizing the biomechanical inputs from both participants while preventing unnatural or jarring forces. By embedding this interactive virtual linkage, TEPI provides continuous haptic feedback to therapists, allowing them to modulate support, resistance, and corrective assistance in tune with patient movement intentions.

In a recent clinical evaluation published in Science Robotics, TEPI demonstrated superior outcomes compared to conventional therapist-guided treadmill training. Stroke survivors using the system achieved significantly greater joint range of motion, executed longer and higher stepping patterns, and maintained muscle activation at levels comparable to or exceeding standard therapy regimes. Importantly, patient motivation and enjoyment remained consistently high, underlining the system’s potential to foster engagement and adherence during demanding rehabilitation processes.

The TEPI platform addresses prominent limitations of current rehabilitation exoskeletons, many of which rely on rigid, preprogrammed gait cycles that lack real-time adaptability. By contrast, TEPI integrates therapist expertise directly into the robotic control loop, enabling instantaneous behavioral adjustments that match the patient’s unique recovery trajectory. This synergy of human judgment and machine assistance embodies a new paradigm in rehabilitation robotics, where technology serves to amplify, not replace, therapeutic skill.

José L. Pons, the project’s visionary leader and a professor at Northwestern, emphasizes that TEPI’s promise lies in its ability to unify the therapeutic closeness of manual training with the replicability and intensity of robotic interventions. Such hybrid systems are poised to transform stroke recovery protocols by bridging gaps between efficacy, accessibility, and individualized care. They not only alleviate therapist physical burden but also enhance the precision and personalization of rehabilitation exercises.

The development team included multidisciplinary experts spanning mechanical engineering, physical medicine, biomedical engineering, and robotics, fostering innovation at the interface of human-machine interaction and clinical practice. This collaboration ensured that TEPI’s control algorithms and mechanical design were continuously refined based on real-world clinical feedback, resulting in a system deeply attuned to both biomechanical and therapeutic demands.

Looking ahead, the research group plans to expand TEPI’s application beyond treadmill walking, exploring its integration into functionally critical daily activities such as overground ambulation, stair climbing, and sit-to-stand transitions. Longitudinal studies are also underway to assess the benefits of repeated therapy sessions over extended recovery periods. Additionally, efforts are progressing to miniaturize and streamline the technology for potential deployment in home environments, promising scalable remote rehabilitation solutions that can transcend geographic and logistical barriers.

TEPI’s pioneering approach was made possible by funding from the U.S. National Science Foundation’s National Robotics Initiative, reflecting the strategic importance of robotics in advancing healthcare outcomes. By embedding robotic exoskeletons within a responsive therapeutic framework, the system exemplifies how cutting-edge engineering can catalyze transformative changes in the treatment of neurological impairments.

This breakthrough not only advances rehabilitation science but also redefines the human role in therapy. TEPI empowers therapists to become active collaborators with their patients through enhanced, augmented physical connection, promoting a more effective and responsive recovery journey for stroke survivors. It stands as a shining example of innovation that is as empathetic as it is technological — a true step forward in restoring mobility and quality of life.

Subject of Research:
Robotic exoskeleton-assisted gait therapy for stroke rehabilitation through therapist-patient real-time interaction.

Article Title:
Therapist-exoskeleton-patient interaction for gait therapy

News Publication Date:
17-Jun-2026

Web References:
http://dx.doi.org/10.1126/scirobotics.adz9628

Image Credits:
Shirley Ryan AbilityLab

Keywords

Robotic exoskeletons, Robotics, Robotic gaits, Robotic walking, Physical therapy, Physical rehabilitation, Brain damage, Brain injuries, Brain ischemia, Neuromuscular diseases, Neurological disorders

In a groundbreaking study that redefines our understanding of how language is encoded in the human brain, researchers have mapped the diverse landscape of neurons distributed across frontal and temporal cortical regions, revealing a complex yet lateralized neural architecture for human language processing. By leveraging advanced single-neuron recording techniques alongside sophisticated language models, the team has identified not just the locations but the nuanced encoding properties of neurons implicated in various linguistic computations. This work illuminates how language, a uniquely human faculty, is instantiated at the neuronal level with precision and regional specificity.

The study’s comprehensive neuronal recordings spanned key brain areas historically associated with language, including the frontal cortex, anterior temporal cortex, and posterior temporal cortex. These regions were chosen given their established roles in speech production and linguistic comprehension, as well as their demonstrated selective responses in prior localized brain imaging studies. Importantly, the neurons examined were broadly distributed across both hemispheres and these cortical regions, showcasing the widespread neural substrate involved in language tasks.

One of the seminal findings was that roughly half of the neurons, 289 out of 579, exhibited selective responsiveness to one or more linguistic features. Intriguingly, this selectivity was evenly distributed across the three cortical sites — frontal, anterior temporal, and posterior temporal — and did not significantly differ between the left and right hemispheres. This suggests a foundational neural scaffold where language-related computations recruit a multitude of neurons across large-scale networks rather than isolated hotspots, emphasizing distributed processing over modular localization.

However, beyond this broad distribution, the study uncovered striking lateralization and regional differentiation in the strength and informational content of neural modulation. Neurons within the left hemisphere exhibited significantly stronger modulation—quantified by their z-scored activity changes—in response to linguistic features compared to their right hemisphere counterparts. This enhanced sensitivity encompassed a range of linguistic elements, including lower-order features like pitch, underscoring the superior role of the left hemisphere in detailed linguistic encoding.

Further dissecting these lateralized effects across cortical regions revealed that the posterior temporal cortex showed the most pronounced difference in left-right modulation strength, significantly outperforming other areas. This aligns well with the notion that posterior temporal areas are central to decoding complex linguistic dependencies and syntactic structures, functions critical for fluent language comprehension and production.

Conversely, the prefrontal cortex displayed the strongest overall neuronal modulation to these language features, both in the left and right hemispheres, compared to temporal regions. This finding suggests a hierarchical and possibly integrative role for the frontal cortex in orchestrating language processing, perhaps linked to higher-order syntactic planning, working memory, or executive control mechanisms required for natural speech.

The neural predictivity analysis, leveraging embeddings from cutting-edge contextual language models, further corroborated the lateralized and regionalized pattern. Neural activity in the left anterior temporal cortex was most accurately predicted by these language model features, highlighting this region’s role in abstract linguistic representation and semantic integration during language tasks.

Methodologically, the study capitalized on the precise temporal resolution of single-neuron recording combined with sophisticated statistical analyses, including permutation and rank-sum tests, to quantify neuronal response selectivity and modulation. This rigorous approach afforded a fine-grained characterization of how individual neurons adapt their firing patterns to various syntactic and prosodic elements of language in real-time.

Collectively, these data challenge conventional notions that neural language processing is confined to narrowly defined “language centers.” Instead, the findings advocate for a model of language representation as a widely distributed but regionally specialized system with marked hemispheric dominance. This has profound implications for understanding the neural basis of language disorders, suggesting that therapeutic interventions might need to consider both distributed network integrity and hemispheric targeting.

Moreover, the study’s integration of naturalistic language models with neurophysiological data marks a pioneering step in computational neuroscience, bridging theoretical frameworks of language with tangible neural mechanisms. By showing how models trained solely on linguistic input can approximate neuronal responses, this research points toward a future where artificial intelligence and neuroscience synergistically unravel human cognition.

Importantly, the results underscore the unique neural architecture supporting language that has evolved in humans, outstripping earlier simplistic models focused on gross anatomical mapping. These advances set the stage for future investigations that might explore how these neuronal populations interact dynamically during complex language tasks such as conversation, narrative comprehension, or bilingual processing.

In conclusion, this landmark research paints a detailed, high-resolution portrait of the neuronal building blocks underpinning human language. It reveals an exquisitely lateralized and regionally differentiated system whereby distributed neurons collectively encode the multifaceted features of speech. Such insights not only deepen fundamental neuroscience but also hold promise for novel clinical interventions and computational linguistic advancements.

---

Subject of Research: Neuronal encoding of human language features across frontal and temporal cortical regions; lateralization and regional differentiation of linguistic processing in the brain.

Article Title: Mapping the neuronal building blocks of human language with language models.

Article References:
Cai, J., Kfir, Y., Jamali, M. et al. Mapping the neuronal building blocks of human language with language models. Nature (2026). https://doi.org/10.1038/s41586-026-10691-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10691-5

JCMT0402-0424, a dusty starburst galaxy around 11 billion light-years away, is the strongest candidate yet for the source of the high-energy neutrino event IC 210922A, according to a team of astronomer led by Yuji Urata of MITOS Science Co.

The post Astronomers Trace Elusive High-Energy Neutrino to Star-Forming Galaxy in Early Universe appeared first on Sci.News: Breaking Science News.

The State Department is taking over much of the control of global health initiatives, for which critics say the department does not have the expertise.

Some stars have planets. Others are orbited by brown dwarfs, balls of gas too massive to be planets, but too low-mass to be stars. Astronomers love these brown dwarf-star pairs because being paired with a star helps reveal a brown dwarf’s age. Ages of astronomical objects are often hard to measure, but essential for understanding how they form. 

Now, you can join NASA’s new Backyard Worlds: Binaries project and help astronomers discover these rare and interesting pairs. As a volunteer, you’ll inspect images from NASA’s Wide-field Infrared Survey Explorer (WISE) space telescope. Brown dwarfs may appear as small dots moving across a field of otherwise static stars. 

“We need your help to gain critical insights into these enigmatic cosmic objects,” said project lead Aaron Meisner.

Brown dwarfs are common but mysterious because they are so faint. There’s one for every three or four stars in our corner of the Milky Way galaxy. They are important laboratories for understanding giant planets like Jupiter.

Join the Backyard Worlds: Binaries project today and help astronomers understand where and when brown dwarfs form! You can also try one of our other brown dwarf-related projects: Backyard Worlds: Cool Neighbors! Anyone with a laptop or cell phone can participate. Participation does not require citizenship in any particular country.

The post Search for Hidden Cosmic Companions in Sun’s Backyard appeared first on NASA Science.

Some stars have planets. Others are orbited by brown dwarfs, balls of gas too massive to be planets, but too low-mass to be stars. Astronomers love these brown dwarf-star pairs because being paired with a star helps reveal a brown dwarf’s age. Ages of astronomical objects are often hard to measure, but essential for understanding how they form. 

Now, you can join NASA’s new Backyard Worlds: Binaries project and help astronomers discover these rare and interesting pairs. As a volunteer, you’ll inspect images from NASA’s Wide-field Infrared Survey Explorer (WISE) space telescope. Brown dwarfs may appear as small dots moving across a field of otherwise static stars. 

“We need your help to gain critical insights into these enigmatic cosmic objects,” said project lead Aaron Meisner.

Brown dwarfs are common but mysterious because they are so faint. There’s one for every three or four stars in our corner of the Milky Way galaxy. They are important laboratories for understanding giant planets like Jupiter.

Join the Backyard Worlds: Binaries project today and help astronomers understand where and when brown dwarfs form! You can also try one of our other brown dwarf-related projects: Backyard Worlds: Cool Neighbors! Anyone with a laptop or cell phone can participate. Participation does not require citizenship in any particular country.

A plain-English guide to AI in 2026, including top chatbots, free AI tools, humanoid robots, key terms, and what comes next.

A US filing says Grok was used in military operations tied to Iran, surfacing through an environmental lawsuit over xAI gas turbines.

The base iPhone 17 supports Apple Intelligence, but Apple’s 12GB memory requirement blocks its most advanced Siri AI features.

Late last week, Anthropic took its new Claude Fable 5 and Mythos 5 AI models offline following a United States government export-control directive barring “any foreign national” from using the services. The company has been in talks with the White House since Friday but has yet to secure an agreement that would allow it to reinstate the offerings.

Since Mythos debuted in April, Anthropic has claimed—and warned—that the model has advanced capabilities for not only finding software vulnerabilities to help defenders patch them, but also figuring out ways to exploit them that could be used by bad actors. Anthropic itself noted this double-edged sword in its launch of Mythos 5 and Claude Fable 5. “A great deal of advanced usage of AI models is dual use: the same queries that are beneficial in the hands of cybersecurity professionals and biology researchers could be dangerous if available to malicious actors,” the company wrote in a blog post last week.

With this in mind, the company initially released a version called Mythos Preview to a select consortium as part of a working group known as Project Glasswing. Mythos 5 was also privately released to this group last week, while Claude Fable 5, which is a Mythos-grade model, was released to the general public with specific blocks on its ability to give responses to questions about biology and cybersecurity.

Read full article

Comments

© Samuel Axon

Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support.

Using NASA’s Goldstone Solar System Radar and NSF’s Green Bank Telescope, astronomers from the University of California, Los Angeles, confirmed that the icy surface of Jupiter’s moon Europa scatters radio energy in an unusually strong and complex way not seen on rocky worlds.

The post Radar Observations Reveal New Clues about Europa’s Hidden Interior appeared first on Sci.News: Breaking Science News.